Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Visceral leishmaniasis (kala-azar): challenges ahead.

Singh RK, Pandey HP, Sundar S.

Indian J Med Res. 2006 Mar;123(3):331-44. Review.

PMID:
16778314
2.

Drug unresponsiveness & combination therapy for kala-azar.

Jha TK.

Indian J Med Res. 2006 Mar;123(3):389-98. Review.

PMID:
16778318
3.

Childhood visceral leishmaniasis.

Bhattacharya SK, Sur D, Karbwang J.

Indian J Med Res. 2006 Mar;123(3):353-6. Review.

PMID:
16778316
4.

Drug resistance in Indian visceral leishmaniasis.

Sundar S.

Trop Med Int Health. 2001 Nov;6(11):849-54. Erratum in: Trop Med Int Health 2002 Mar;7(3):293.

5.

Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.

Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.

J Assoc Physicians India. 2003 Jul;51:686-90. Review.

PMID:
14621038
6.

Leishmaniasis in Sudan. Visceral leishmaniasis.

Zijlstra EE, el-Hassan AM.

Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S27-58.

PMID:
11370250
7.

Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Mishra J, Madhubala R, Singh S.

Parasitol Res. 2013 Mar;112(3):1001-9. doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18.

PMID:
23242321
8.

Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.

Thakur CP, Dedet JP, Narain S, Pratlong F.

Trans R Soc Trop Med Hyg. 2001 Mar-Apr;95(2):187-9.

PMID:
11355558
9.

Management of visceral leishmaniasis: Indian perspective.

Agrawal S, Rai M, Sundar S.

J Postgrad Med. 2005;51 Suppl 1:S53-7. Review.

10.

Leishmaniasis.

Herwaldt BL.

Lancet. 1999 Oct 2;354(9185):1191-9. Review.

PMID:
10513726
11.

Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.

Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P.

Parasitol Res. 2012 Oct;111(4):1559-68. Epub 2012 Jul 1.

PMID:
22752721
12.

Visceral leishmaniasis - current therapeutic modalities.

Sundar S, Chatterjee M.

Indian J Med Res. 2006 Mar;123(3):345-52. Review.

PMID:
16778315
13.

Kala-azar--new developments in diagnosis and treatment.

Aggarwal P, Handa R, Singh S, Wali JP.

Indian J Pediatr. 1999 Jan-Feb;66(1):63-71. Review.

PMID:
10798038
14.

Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.

Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A.

Indian J Med Res. 2008 Jul;128(1):38-44.

PMID:
18820357
15.

Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.

Sinha PK, Ranjan A, Singh VP, Das VN, Pandey K, Kumar N, Verma N, Lal CS, Sur D, Manna B, Bhattacharya SK.

J Infect. 2006 Jul;53(1):60-4. Epub 2005 Nov 2.

PMID:
16269185
16.
17.

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD.

Lancet Infect Dis. 2002 Aug;2(8):494-501. Review.

PMID:
12150849
18.
19.

The treatment of visceral leishmaniasis: safety and efficacy.

Jha RK, Sah AK, Shah DK, Sah P.

JNMA J Nepal Med Assoc. 2013 Oct-Dec;52(192):645-51. Review.

PMID:
25327244
20.

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.

Patra P, Guha SK, Maji AK, Saha P, Ganguly S, Chakraborty A, Kundu PK, Sarker S, Ray K.

Indian J Pharmacol. 2012 Jul-Aug;44(4):500-3. doi: 10.4103/0253-7613.99326.

Supplemental Content

Support Center